Compare Incyte Corporation (INCY) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Norwegian Cruise Line Holdings Ltd — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Norwegian Cruise Line Holdings Ltd trades at $19.59 (market cap $8.95B). The key difference: Incyte Corporation is far larger — about 2.6× Norwegian Cruise Line Holdings Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | NCLH | |
|---|---|---|
Market Cap | $23.11B | $8.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $26.94 |
52-Week Low | $67.38 | $14.79 |
Enterprise Value | $19.13B | $23.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Norwegian Cruise Line Holdings (NCLH) trades at $19.47, showing minimal daily movement with a 0.05% gain. The stock demonstrates strong fundamental momentum with three consecutive quarterly earnings beats and improving profitability metrics. Recent technical indicators show mixed signals with a bearish overall trend but neutral oscillators. The company maintains solid revenue growth, reaching $9.83 billion in 2025, while navigating significant capital expenditures for fleet expansion.
NCLH presents a compelling value opportunity with attractive valuation ratios (P/E: 15.69, P/S: 0.94) and strong analyst support (55.55% buy ratings). However, investors face risks from high debt levels ($13.1 billion total debt) and sensitivity to macroeconomic factors affecting travel demand. The upcoming Q2 2026 earnings report on July 30 represents a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
